{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:24:48Z","timestamp":1778912688735,"version":"3.51.4"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,10,20]],"date-time":"2005-10-20T00:00:00Z","timestamp":1129766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1038\/nrc1739","type":"journal-article","created":{"date-parts":[[2005,10,20]],"date-time":"2005-10-20T13:19:22Z","timestamp":1129814362000},"page":"845-856","source":"Crossref","is-referenced-by-count":1377,"title":["Biomarkers in Cancer Staging, Prognosis and Treatment Selection"],"prefix":"10.1038","volume":"5","author":[{"given":"Joseph A.","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,20]]},"reference":[{"key":"BFnrc1739_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ssu.10014","volume":"21","author":"LH Sobin","year":"2003","unstructured":"Sobin, L. H. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol. 21, 3\u20137 (2003). Historical perspective of the TNM staging guidelines.","journal-title":"Semin. Surg. Oncol."},{"key":"BFnrc1739_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1053\/sonc.2002.32896","volume":"29","author":"ME Hammond","year":"2002","unstructured":"Hammond, M. E. & Taube, S. E. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 29, 213\u2013221 (2002). Provides useful guidelines for the discovery, evaluation and validation of clinical biomarkers.","journal-title":"Semin. Oncol."},{"key":"BFnrc1739_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S1471-4914(02)02353-5","volume":"8","author":"RS Negm","year":"2002","unstructured":"Negm, R. S., Verma, M. & Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8, 288\u2013293 (2002).","journal-title":"Trends Mol. Med."},{"key":"BFnrc1739_CR4","unstructured":"US Department of Health & Human Services; US Food and Drug Administration. Challenge and Opportunity on the Critical Path of New Medical Products. http:\/\/www.fda.gov\/oc\/initiatives\/criticalpath\/whitepaper.html (2004)."},{"key":"BFnrc1739_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","volume":"1","author":"NL Anderson","year":"2002","unstructured":"Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845\u2013867 (2002).","journal-title":"Mol. Cell. Proteomics"},{"key":"BFnrc1739_CR6","first-page":"5243","volume":"63","author":"S Nishizuka","year":"2003","unstructured":"Nishizuka, S. et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243\u20135250 (2003). Clear demonstration that numerous genomic, proteomic and tissue-based arrays can be used in concert to distinguish between colon and ovarian carcinomas.","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jnci\/90.13.972","volume":"90","author":"PP Leong","year":"1998","unstructured":"Leong, P. P. et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J. Natl Cancer Inst. 90, 972\u2013977 (1998).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/91.7.599","volume":"91","author":"J Califano","year":"1999","unstructured":"Califano, J. et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J. Natl Cancer Inst. 91, 599\u2013604 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR9","first-page":"347","volume":"6","author":"J Califano","year":"2000","unstructured":"Califano, J. et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6, 347\u2013352 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR10","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.0931261100","volume":"100","author":"X Ma","year":"2003","unstructured":"Ma, X. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974\u20135979 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00006254-199904000-00022","volume":"54","author":"O Abulafia","year":"1999","unstructured":"Abulafia, O. & Sherer, D. M. Automated cervical cytology: meta-analyses of the performance of the PAPNET system. Obst. Gynecol. Surv. 54, 253\u2013264 (1999).","journal-title":"Obst. Gynecol. Surv."},{"key":"BFnrc1739_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1148\/radiol.2322030034","volume":"232","author":"SV Destounis","year":"2004","unstructured":"Destounis, S. V. et al. Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. Radiology 232, 578\u2013584 (2004).","journal-title":"Radiology"},{"key":"BFnrc1739_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1148\/radiol.2302030049","volume":"230","author":"K Awai","year":"2004","unstructured":"Awai, K. et al. Pulmonary nodules at chest CT: effect of computer-aided diagnosis on radiologists' detection performance. Radiology 230, 347\u2013352 (2004).","journal-title":"Radiology"},{"key":"BFnrc1739_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10278-002-0011-x","volume":"15","author":"BJ Erickson","year":"2002","unstructured":"Erickson, B. J. & Bartholmai, B. Computer-aided detection and diagnosis at the start of the third millennium. J. Digit. Imaging 15, 59\u201368 (2002).","journal-title":"J. Digit. Imaging"},{"key":"BFnrc1739_CR15","unstructured":"American Joint Committee on Cancer & American Cancer Society. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (eds Greene, F. L. et al.) (Springer, New York, 2002). AJCC guidelines for cancer staging."},{"key":"BFnrc1739_CR16","first-page":"209","volume":"47","author":"P McQuade","year":"2003","unstructured":"McQuade, P. & Knight, L. C. Radiopharmaceuticals for targeting the angiogenesis marker \u03b1v\u03b23 . Q. J. Nucl. Med. 47, 209\u2013220 (2003).","journal-title":"Q. J. Nucl. Med."},{"key":"BFnrc1739_CR17","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1073\/pnas.95.11.6349","volume":"95","author":"FG Blankenberg","year":"1998","unstructured":"Blankenberg, F. G. et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl Acad. Sci. USA 95, 6349\u20136354 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR18","first-page":"309","volume":"45","author":"Y Kuge","year":"2004","unstructured":"Kuge, Y. et al. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 45, 309\u2013312 (2004).","journal-title":"J. Nucl. Med."},{"key":"BFnrc1739_CR19","first-page":"174","volume":"45","author":"KA Krohn","year":"2001","unstructured":"Krohn, K. A. Evaluation of alternative approaches for imaging cellular growth. Q. J. Nucl. Med. 45, 174\u2013178 (2001).","journal-title":"Q. J. Nucl. Med."},{"key":"BFnrc1739_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1148\/rg.232025705","volume":"23","author":"L Kostakoglu","year":"2003","unstructured":"Kostakoglu, L., Agress, H. Jr & Goldsmith, S. J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23, 315\u2013340 (2003).","journal-title":"Radiographics"},{"key":"BFnrc1739_CR21","first-page":"224","volume":"44","author":"L Kostakoglu","year":"2003","unstructured":"Kostakoglu, L. & Goldsmith, S. J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44, 224\u2013239 (2003).","journal-title":"J. Nucl. Med."},{"key":"BFnrc1739_CR22","first-page":"1945","volume":"44","author":"SH Britz-Cunningham","year":"2003","unstructured":"Britz-Cunningham, S. H. & Adelstein, S. J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 44, 1945\u20131961 (2003).","journal-title":"J. Nucl. Med."},{"key":"BFnrc1739_CR23","first-page":"650","volume":"9","author":"M Agrawal","year":"2003","unstructured":"Agrawal, M. et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650\u2013656 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0959-8049(97)10157-5","volume":"34","author":"F Revillion","year":"1998","unstructured":"Revillion, F., Bonneterre, J. & Peyrat, J. P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 34, 791\u2013808 (1998).","journal-title":"Eur. J. Cancer"},{"key":"BFnrc1739_CR25","first-page":"5675","volume":"54","author":"MF Press","year":"1994","unstructured":"Press, M. F. et al. Amplification and overexpression of HER-2\/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 54, 5675\u20135682 (1994).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR26","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","volume":"20","author":"SE Singletary","year":"2002","unstructured":"Singletary, S. E. et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628\u20133636 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1739_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Activity of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038\u20131042 (2001).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrc1739_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/ng1107","volume":"33","author":"A Balmain","year":"2003","unstructured":"Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33 (Suppl.), 238\u2013244 (2003).","journal-title":"Nature Genet."},{"key":"BFnrc1739_CR29","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1739_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004). Evidence that subtle mutations in EGFR can affect the clinical response to gefitinib.","journal-title":"Science"},{"key":"BFnrc1739_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.lungcan.2004.04.032","volume":"46","author":"H Kaneda","year":"2004","unstructured":"Kaneda, H. et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46, 247\u2013254 (2004).","journal-title":"Lung Cancer"},{"key":"BFnrc1739_CR32","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","volume":"19","author":"PM Ravdin","year":"2001","unstructured":"Ravdin, P. M. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19, 980\u2013991 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1739_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/35101056","volume":"1","author":"M Relling","year":"2001","unstructured":"Relling, M. & Dervieux, T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99\u2013108 (2001).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1739_CR34","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.2004.04.900","volume":"22","author":"HJ Lenz","year":"2004","unstructured":"Lenz, H. J. The use and development of germline polymorphisms in clinical oncology. J. Clin. Oncol. 22, 2519\u20132521 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1739_CR35","first-page":"646","volume":"37","author":"SA Leon","year":"1977","unstructured":"Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646\u2013650 (1977).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrc755","volume":"2","author":"D Sidransky","year":"2002","unstructured":"Sidransky, D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210\u2013219 (2002). In-depth review of diverse biomarkers undergoing clinical evaluation.","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1739_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/B:BREA.0000036897.92513.72","volume":"86","author":"HJ Kahn","year":"2004","unstructured":"Kahn, H. J. et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res. Treat. 86, 237\u2013247 (2004).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrc1739_CR38","first-page":"5145","volume":"9","author":"A Stathopoulou","year":"2003","unstructured":"Stathopoulou, A. et al. Real-time quantification of CK-19 mrna-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 9, 5145\u20135151 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR39","first-page":"2253","volume":"60","author":"DS Hoon","year":"2000","unstructured":"Hoon, D. S. et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60, 2253\u20132257 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/bcr942","volume":"6","author":"V Muller","year":"2004","unstructured":"Muller, V. & Pantel, K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res. 6, 258\u2013261 (2004).","journal-title":"Breast Cancer Res."},{"key":"BFnrc1739_CR41","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrc1370","volume":"4","author":"K Pantel","year":"2004","unstructured":"Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448\u2013456 (2004).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1739_CR42","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152\u20138162 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJM199502163320704","volume":"332","author":"JA Brennon","year":"1995","unstructured":"Brennon, J. A. et al. Molecular assesment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429\u2013435 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1739_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","volume":"88","author":"AJ Levine","year":"1997","unstructured":"Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323\u2013331 (1997).","journal-title":"Cell"},{"key":"BFnrc1739_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/342705a0","volume":"342","author":"JM Nigro","year":"1989","unstructured":"Nigro, J. M., et al. Mutations in the p53 gene occur in diverse tumor types. Nature 342, 705\u2013708 (1989).","journal-title":"Nature"},{"key":"BFnrc1739_CR46","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1739_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nm0795-686","volume":"1","author":"A Merlo","year":"1995","unstructured":"Merlo, A. et al. 5\u2032 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16\/CDKN2\/MTS1 in human cancers. Nature Med. 1, 686\u2013692 (1995).","journal-title":"Nature Med."},{"key":"BFnrc1739_CR48","doi-asserted-by":"publisher","first-page":"9700","DOI":"10.1073\/pnas.91.21.9700","volume":"91","author":"JG Herman","year":"1994","unstructured":"Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by dna methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700\u20139704 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR49","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein, T. & Allis, C. Translating the histone code. Science 293, 1074\u20131080 (2001).","journal-title":"Science"},{"key":"BFnrc1739_CR50","first-page":"3225","volume":"61","author":"M Esteller","year":"2001","unstructured":"Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225\u20133229 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR51","doi-asserted-by":"publisher","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","volume":"93","author":"JG Herman","year":"1996","unstructured":"Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821\u20139826 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR52","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1073\/pnas.89.5.1827","volume":"89","author":"M Frommer","year":"1992","unstructured":"Frommer, M. et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual dna strands. Proc. Natl Acad. Sci. USA 89, 1827\u20131831 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR53","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/jnci\/93.22.1747","volume":"93","author":"C Jeronimo","year":"2001","unstructured":"Jeronimo, C. et al. Quantitation of GTSP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747\u20131752 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR54","first-page":"939","volume":"61","author":"SL Rosas","year":"2001","unstructured":"Rosas, S. L. et al. Promoter hypermethylation patterns of p16, o6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939\u2013942 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR55","doi-asserted-by":"publisher","first-page":"11891","DOI":"10.1073\/pnas.95.20.11891","volume":"95","author":"SA Belinsky","year":"1998","unstructured":"Belinsky, S. A. et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891\u201311896 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR56","first-page":"5954","volume":"60","author":"WA Palmisano","year":"2000","unstructured":"Palmisano, W. A. et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954\u20135958 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/jnci\/91.4.332","volume":"91","author":"SA Ahrendt","year":"1999","unstructured":"Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332\u2013339 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0304-3835(02)00740-1","volume":"193","author":"JL Ramirez","year":"2003","unstructured":"Ramirez, J. L. et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 193, 207\u2013216 (2003).","journal-title":"Cancer Lett."},{"key":"BFnrc1739_CR59","first-page":"371","volume":"62","author":"H Usadel","year":"2002","unstructured":"Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371\u2013375 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR60","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0302-2838(02)00468-2","volume":"42","author":"MT Valenzuela","year":"2002","unstructured":"Valenzuela, M. T. et al. Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42, 622\u2013630 (2002).","journal-title":"Eur. Urol."},{"key":"BFnrc1739_CR61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ijc.11117","volume":"105","author":"H Nakayama","year":"2003","unstructured":"Nakayama, H. et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int. J. Cancer 105, 491\u2013493 (2003).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1739_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0304-3835(03)00055-7","volume":"194","author":"S Yamaguchi","year":"2003","unstructured":"Yamaguchi, S., Asao, T., Nakamura, J. I., Ide, M. & Kuwano, H. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett. 194, 99\u2013105 (2003).","journal-title":"Cancer Lett."},{"key":"BFnrc1739_CR63","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl J. Med. 343, 1350\u20131354 (2000).","journal-title":"N. Engl J. Med."},{"key":"BFnrc1739_CR64","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJM200011093431910","volume":"343","author":"JN Weinstein","year":"2000","unstructured":"Weinstein, J. N. Pharmacogenomics \u2014 teaching old drugs new tricks. N. Engl. J. Med. 343, 1408\u20131409 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1739_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/01.cco.0000147383.04709.10","volume":"17","author":"M Esteller","year":"2005","unstructured":"Esteller, M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17, 55\u201360 (2005).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrc1739_CR66","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ccr.2004.06.023","volume":"6","author":"JC Cheng","year":"2004","unstructured":"Cheng, J. C. et al. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151\u2013158 (2004).","journal-title":"Cancer Cell"},{"key":"BFnrc1739_CR67","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2174\/1381612043383980","volume":"10","author":"R Piekarz","year":"2004","unstructured":"Piekarz, R. & Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10, 2289\u20132298 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrc1739_CR68","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","volume":"103","author":"RL Piekarz","year":"2004","unstructured":"Piekarz, R. L. et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103, 4636\u20134643 (2004).","journal-title":"Blood"},{"key":"BFnrc1739_CR69","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrn1518","volume":"5","author":"PS Mischel","year":"2004","unstructured":"Mischel, P. S., Cloughesy, T. F. & Nelson, S. F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Rev. Neurosci. 5, 782\u2013792 (2004).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrc1739_CR70","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/carcin\/21.3.443","volume":"21","author":"JW Gray","year":"2000","unstructured":"Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumors. Carcinogenesis 21, 443\u2013452 (2000).","journal-title":"Carcinogenesis"},{"key":"BFnrc1739_CR71","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.270.5235.484","volume":"270","author":"VE Velculescu","year":"1995","unstructured":"Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Serial analysis of gene expression. Science 270, 484\u2013487 (1995).","journal-title":"Science"},{"key":"BFnrc1739_CR72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0169-409X(02)00223-5","volume":"55","author":"BH Weigl","year":"2003","unstructured":"Weigl, B. H., Bardell, R. L. & Cabrera, C. R. Lab-on-a-chip for drug development. Adv. Drug. Deliv. Rev. 55, 349\u2013377 (2003).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"BFnrc1739_CR73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","volume":"275","author":"JN Weinstein","year":"1997","unstructured":"Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343\u2013349 (1997).","journal-title":"Science"},{"key":"BFnrc1739_CR74","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrm1570","volume":"6","author":"J Papin","year":"2005","unstructured":"Papin, J. A, Hunter, T., Palsson, B. O. & Subramaniam, S. Reconstruction of cellular signalling networks and analysis of their properties. Nature Rev. Mol. Cell Biol. 6, 99\u2013111 (2005).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrc1739_CR75","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrd891","volume":"1","author":"EF Petricoin","year":"2002","unstructured":"Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1, 683\u2013695 (2002). Comprehensive review of clinical proteomic technologies and associated pattern-based protein markers.","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc1739_CR76","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"C Perou","year":"2000","unstructured":"Perou, C. et al. Molecular portraits of human breast tumours. Nature 406, 747\u2013752 (2000).","journal-title":"Nature"},{"key":"BFnrc1739_CR77","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie, T., Perou, C., Brown, P., Botstein, D. & Borresen-Dale, A. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869\u201310874 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR78","doi-asserted-by":"publisher","first-page":"10393","DOI":"10.1073\/pnas.1732912100","volume":"100","author":"C Sotiriou","year":"2003","unstructured":"Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393\u201310398 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR79","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999\u20132009 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1739_CR80","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van't Veer","year":"2002","unstructured":"van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530\u2013536 (2002).","journal-title":"Nature"},{"key":"BFnrc1739_CR81","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","volume":"362","author":"JC Chang","year":"2003","unstructured":"Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362\u2013369 (2003).","journal-title":"Lancet"},{"key":"BFnrc1739_CR82","doi-asserted-by":"crossref","unstructured":"Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).","DOI":"10.1186\/bcr433"},{"key":"BFnrc1739_CR83","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ng1060","volume":"33","author":"S Ramaswamy","year":"2003","unstructured":"Ramaswamy, S., Ross, K., Lander, E. & Golub, T. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49\u201354 (2003).","journal-title":"Nature Genet."},{"key":"BFnrc1739_CR84","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-03-0156","volume":"10","author":"R Rosell","year":"2004","unstructured":"Rosell, R. et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318\u20131325 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR85","first-page":"1322","volume":"6","author":"D Salonga","year":"2000","unstructured":"Salonga, D. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322\u20131327 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR86","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/35020115","volume":"406","author":"M Bittner","year":"2000","unstructured":"Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536\u2013540 (2000).","journal-title":"Nature"},{"key":"BFnrc1739_CR87","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1038\/sj.onc.1206448","volume":"22","author":"KM Carr","year":"2003","unstructured":"Carr, K. M., Bittner, M. & Trent, J. M. Gene-expression profiling in human cutaneous melanoma. Oncogene 22, 3076\u20133080 (2003).","journal-title":"Oncogene"},{"key":"BFnrc1739_CR88","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/science.286.5439.531","volume":"286","author":"TR Golub","year":"1999","unstructured":"Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531\u2013537 (1999).","journal-title":"Science"},{"key":"BFnrc1739_CR89","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"BFnrc1739_CR90","doi-asserted-by":"publisher","first-page":"8886","DOI":"10.1073\/pnas.132253599","volume":"99","author":"IS Lossos","year":"2002","unstructured":"Lossos, I. S. et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl Acad. Sci. USA 99, 8886\u20138891 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR91","doi-asserted-by":"publisher","first-page":"13784","DOI":"10.1073\/pnas.241500798","volume":"98","author":"ME Garber","year":"2001","unstructured":"Garber, M. E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784\u201313789 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00019606-200306000-00001","volume":"12","author":"CJ Best","year":"2003","unstructured":"Best, C. J. et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol. 12, 63\u201370 (2003).","journal-title":"Diagn. Mol. Pathol."},{"key":"BFnrc1739_CR93","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1038\/sj.onc.1205613","volume":"21","author":"TT Zou","year":"2002","unstructured":"Zou, T. T. et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21, 4855\u20134862 (2002).","journal-title":"Oncogene"},{"key":"BFnrc1739_CR94","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1074\/mcp.M100015-MCP200","volume":"1","author":"G Zhou","year":"2002","unstructured":"Zhou, G. et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics 1, 117\u2013124 (2002).","journal-title":"Mol. Cell. Proteomics"},{"key":"BFnrc1739_CR95","doi-asserted-by":"publisher","first-page":"14229","DOI":"10.1073\/pnas.2331323100","volume":"100","author":"S Nishizuka","year":"2003","unstructured":"Nishizuka, S. et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100, 14229\u201314234 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1739_CR96","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/sj.onc.1204265","volume":"20","author":"CP Paweletz","year":"2001","unstructured":"Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981\u20131989 (2001).","journal-title":"Oncogene"},{"key":"BFnrc1739_CR97","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1749-6632.2001.tb03870.x","volume":"945","author":"M Verma","year":"2001","unstructured":"Verma, M., Wright, G. L. Jr, Hanash, S. M., Gopal-Srivastava, R. & Srivastava, S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. NY Acad. Sci. 945, 103\u2013115 (2001).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrc1739_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrc1043","volume":"3","author":"JD Wulfkuhle","year":"2003","unstructured":"Wulfkuhle, J. D., Liotta, L. A. & Petricoin, E. F. Proteomic applications for the early detection of cancer. Nature Rev. Cancer 3, 267\u2013275 (2003).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1739_CR99","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1126\/science.1439758","volume":"258","author":"T Sano","year":"1992","unstructured":"Sano, T., Smith, C. L. & Cantor, C. R. Immuno-PCR: very sensitive antigen detection by means of specific antibody\u2013DNA conjugates. Science 258, 120\u2013122 (1992).","journal-title":"Science"},{"key":"BFnrc1739_CR100","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1126\/science.1088755","volume":"301","author":"JM Nam","year":"2003","unstructured":"Nam, J. M., Thaxton, C. S. & Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884\u20131886 (2003).","journal-title":"Science"},{"key":"BFnrc1739_CR101","first-page":"242","volume":"300","author":"RF Service","year":"2003","unstructured":"Service, R. F. American Chemical Society Meeting. Tiny transistors scout for cancer. Science 300, 242\u2013243 (2003).","journal-title":"Science"},{"key":"BFnrc1739_CR102","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.300.5616.80","volume":"300","author":"C Seydel","year":"2003","unstructured":"Seydel, C. Quantum dots get wet. Science 300, 80\u201381 (2003).","journal-title":"Science"},{"key":"BFnrc1739_CR103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nbt764","volume":"21","author":"X Wu","year":"2003","unstructured":"Wu, X. et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol. 21, 41\u201346 (2003).","journal-title":"Nature Biotechnol."},{"key":"BFnrc1739_CR104","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/jnci\/95.7.502","volume":"95","author":"ET Ben-Ari","year":"2003","unstructured":"Ben-Ari, E. T. Nanoscale quantum dots hold promise for cancer applications. J. Natl Cancer Inst. 95, 502\u2013504 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR105","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nmat961","volume":"2","author":"M Igor","year":"2003","unstructured":"Igor, M. et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nature Mater. 2, 630\u2013638 (2003).","journal-title":"Nature Mater."},{"key":"BFnrc1739_CR106","first-page":"6740","volume":"62","author":"JD Wulfkuhle","year":"2002","unstructured":"Wulfkuhle, J. D. et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62, 6740\u20136749 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR107","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/1615-9861(200110)1:10<1205::AID-PROT1205>3.0.CO;2-X","volume":"1","author":"JD Wulfkuhle","year":"2001","unstructured":"Wulfkuhle, J. D. et al. New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205\u20131215 (2001).","journal-title":"Proteomics"},{"key":"BFnrc1739_CR108","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/1615-9861(200201)2:1<76::AID-PROT76>3.0.CO;2-O","volume":"2","author":"MB Jones","year":"2002","unstructured":"Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76\u201384 (2002).","journal-title":"Proteomics"},{"key":"BFnrc1739_CR109","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/10454411010120010401","volume":"12","author":"V Patel","year":"2001","unstructured":"Patel, V., Leethanakul, C. & Gutkind, J. S. New approaches to the understanding of the molecular basis of oral cancer. Crit. Rev. Oral Biol. Med. 12, 55\u201363 (2001).","journal-title":"Crit. Rev. Oral Biol. Med."},{"key":"BFnrc1739_CR110","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A","volume":"21","author":"DK Ornstein","year":"2000","unstructured":"Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235\u20132242 (2000).","journal-title":"Electrophoresis"},{"key":"BFnrc1739_CR111","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","volume":"93","author":"MS Pepe","year":"2001","unstructured":"Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054\u20131061 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR112","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1749-6632.2003.tb05969.x","volume":"983","author":"PE Barker","year":"2003","unstructured":"Barker, P. E. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann. NY Acad. Sci. 983, 142\u2013150 (2003).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrc1739_CR113","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrc1322","volume":"4","author":"DF Ransohoff","year":"2004","unstructured":"Ransohoff, D. F. Rules of evidence for cancer molecular marker discovery and validation. Nature Rev. Cancer 4, 309\u2013314 (2004). Effectively summarizes the problem of data overfitting in discovery-based research and the need for 'rules of evidence' to ensure clinical validity.","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1739_CR114","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/sonc.2002.33140","volume":"29","author":"S Gutman","year":"2002","unstructured":"Gutman, S. Regulatory issues in tumor marker development. Semin. Oncol. 29, 294\u2013300 (2002). Examines the regulatory environment surrounding biomarker approval by the FDA and CMS.","journal-title":"Semin. Oncol."},{"key":"BFnrc1739_CR115","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1078-1439(00)00076-4","volume":"5","author":"SE Taube","year":"2000","unstructured":"Taube, S. E. & Freiberg, G. P. Regulatory issues related to marker development. Urol. Oncol. 5, 214\u2013216 (2000).","journal-title":"Urol. Oncol."},{"key":"BFnrc1739_CR116","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nbt0703-742","volume":"21","author":"JL Hackett","year":"2003","unstructured":"Hackett, J. L. & Lesko, L. J. Microarray data \u2014 the US FDA, industry and academia. Nature Biotechnol. 21, 742\u2013743 (2003).","journal-title":"Nature Biotechnol."},{"key":"BFnrc1739_CR117","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nbt0698-520","volume":"16","author":"AR Mendelsohn","year":"1998","unstructured":"Mendelsohn, A. R. & Brent, R. Postgenomic protein analysis: the next bend in the river. Nature Biotechnol. 16, 520\u2013521 (1998).","journal-title":"Nature Biotechnol."},{"key":"BFnrc1739_CR118","doi-asserted-by":"crossref","unstructured":"Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8\u2013R17 (2004).","DOI":"10.1186\/bcr658"},{"key":"BFnrc1739_CR119","first-page":"37","volume":"6","author":"JG Einspahr","year":"1997","unstructured":"Einspahr, J. G. et al. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 6, 37\u201348 (1997).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"Suppl. 4","key":"BFnrc1739_CR120","doi-asserted-by":"publisher","first-page":"L87","DOI":"10.1007\/s00330-003-1964-y","volume":"13","author":"K Togashi","year":"2003","unstructured":"Togashi, K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur. Radiol. 13 (Suppl. 4), L87\u2013L104 (2003).","journal-title":"Eur. Radiol."},{"key":"BFnrc1739_CR121","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/archsurg.138.9.951","volume":"138","author":"MG Schlieman","year":"2003","unstructured":"Schlieman, M. G., Ho, H. S. & Bold, R. J. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 138, 951\u2013956 (2003).","journal-title":"Arch. Surg."},{"key":"BFnrc1739_CR122","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF01212949","volume":"121","author":"P Depres-Brummer","year":"1995","unstructured":"Depres-Brummer, P. et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 121, 419\u2013422 (1995).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BFnrc1739_CR123","first-page":"16","volume":"17","author":"JL Duncan","year":"1991","unstructured":"Duncan, J. L., Price, A. & Rogers, K. The use of CA15.3 as a serum tumour marker in breast carcinoma. Eur. J. Surg. Oncol 17, 16\u201319 (1991).","journal-title":"Eur. J. Surg. Oncol"},{"key":"BFnrc1739_CR124","first-page":"181","volume":"7","author":"M Gion","year":"2001","unstructured":"Gion, M. et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J. 7, 181\u2013190 (2001).","journal-title":"Cancer J."},{"key":"BFnrc1739_CR125","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ijc.11249","volume":"106","author":"BL Chang","year":"2003","unstructured":"Chang, B. L. et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int. J. Cancer 106, 375\u2013378 (2003).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1739_CR126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0304-3835(02)00381-6","volume":"187","author":"SG Lee","year":"2002","unstructured":"Lee, S. G. et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 187, 53\u201360 (2002).","journal-title":"Cancer Lett."},{"key":"BFnrc1739_CR127","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/ng1197-341","volume":"17","author":"A Petrij-Bosch","year":"1997","unstructured":"Petrij-Bosch, A. et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 17, 341\u2013345 (1997).","journal-title":"Nature Genet."},{"key":"BFnrc1739_CR128","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jama.279.12.915","volume":"279","author":"B Newman","year":"1998","unstructured":"Newman, B. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279, 915\u2013921 (1998).","journal-title":"JAMA"},{"key":"BFnrc1739_CR129","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jnci\/94.9.681","volume":"94","author":"X Wu","year":"2002","unstructured":"Wu, X. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl Cancer Inst. 94, 681\u2013690 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1739_CR130","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1101\/gr.483802","volume":"12","author":"PE Bonnen","year":"2002","unstructured":"Bonnen, P. E., Wang, P. J., Kimmel, M., Chakraborty, R. & Nelson, D. L. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12, 1846\u20131853 (2002).","journal-title":"Genome Res."},{"key":"BFnrc1739_CR131","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/ng1001-233","volume":"29","author":"G Johnson","year":"2001","unstructured":"Johnson, G. & Todd, J. Haplotype tagging for the identification of common disease genes. Nature Genet. 29, 233\u2013237 (2001).","journal-title":"Nature Genet."},{"key":"BFnrc1739_CR132","first-page":"2216","volume":"63","author":"MO Hoque","year":"2003","unstructured":"Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63, 2216\u20132222 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1739_CR133","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1038\/sj.onc.1207329","volume":"23","author":"PA Janne","year":"2004","unstructured":"Janne, P. A. et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 23, 2716\u20132726 (2004).","journal-title":"Oncogene"},{"key":"BFnrc1739_CR134","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/nm1295-1274","volume":"1","author":"C Boshoff","year":"1995","unstructured":"Boshoff, C. et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Med. 1, 1274\u20131278 (1995).","journal-title":"Nature Med."},{"key":"BFnrc1739_CR135","first-page":"3254","volume":"9","author":"EWH To","year":"2003","unstructured":"To, E. W. H. et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9, 3254\u20133259 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1739_CR136","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/cncr.11496","volume":"98","author":"SF Leung","year":"2003","unstructured":"Leung, S. F. et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98, 288\u2013291 (2003).","journal-title":"Cancer"},{"issue":"Suppl. 8","key":"BFnrc1739_CR137","first-page":"259","volume":"103","author":"N Mueller","year":"1995","unstructured":"Mueller, N. Overview: viral agents and cancer. Environ. Health Perspect. 103 (Suppl. 8), 259\u2013261 (1995).","journal-title":"Environ. Health Perspect."},{"key":"BFnrc1739_CR138","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645\u20131651 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1739_CR139","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1046\/j.0022-202x.2001.01465.x","volume":"117","author":"C Pellet","year":"2001","unstructured":"Pellet, C. et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J. Invest. Dermatol. 117, 858\u2013863 (2001).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrc1739_CR140","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/3108","volume":"20","author":"K Polyak","year":"1998","unstructured":"Polyak, K. et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genet. 20, 291\u2013293 (1998).","journal-title":"Nature Genet."},{"key":"BFnrc1739_CR141","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1383-5742(00)00063-6","volume":"488","author":"NO Bianchi","year":"2001","unstructured":"Bianchi, N. O., Bianchi, M. S. & Richard, S. M. Mitochondrial genome instability in human cancers. Mutat. Res. 488, 9\u201323 (2001).","journal-title":"Mutat. Res."},{"key":"BFnrc1739_CR142","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/gcc.2870010112","volume":"1","author":"C Welter","year":"1989","unstructured":"Welter, C., Kovacs, G., Seitz, G. & Blin, N. Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1, 79\u201382 (1989).","journal-title":"Chromosomes Cancer"},{"key":"BFnrc1739_CR143","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1126\/science.287.5460.2017","volume":"287","author":"MS Fliss","year":"2000","unstructured":"Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017\u20132019 (2000).","journal-title":"Science"},{"key":"BFnrc1739_CR144","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1126\/science.282.5389.627g","volume":"282","author":"JN Weinstein","year":"1998","unstructured":"Weinstein, J. N. Fishing expeditions. Science 282, 628\u2013629 (1998).","journal-title":"Science"},{"key":"BFnrc1739_CR145","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1471-4892(02)00185-6","volume":"2","author":"JN Weinstein","year":"2002","unstructured":"Weinstein, J. N. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr. Opin. Pharmacol. 2, 361\u2013365 (2002).","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc1739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1739","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:18:50Z","timestamp":1684466330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc1739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,20]]},"references-count":145,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["BFnrc1739"],"URL":"https:\/\/doi.org\/10.1038\/nrc1739","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,20]]}}}